SecBot SecBot
SECBOTREPLAY Home › Report › OCUL

OCUL · Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of…

Ocular Therapeutix, Inc. · PRESS-RELEASE filed May 5, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 5, 2026 at 07:00 ET

Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was below the $12.7M estimate. The beat was driven by lower-than-expected operating expenses, but the net loss widened to -$88.6M from -$64.1M YoY due to increased R&D spending on AXPAXLI trials. The stock will move on the EPS beat and positive SOL-1 data momentum, offset by revenue miss and cash burn concerns.

  • EPS of -$0.29 beat consensus of -$0.32 by 9.4%
  • Revenue of $10.8M missed consensus of $12.7M by 15%
  • Net loss widened to -$88.6M from -$64.1M YoY
  • Cash balance $666.7M, expected runway into 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access